ERBB2 and breast cancer: The main pathological subtypes of BC are endocrine-dependent BC (treated with estrogen receptor-α [ERα] antagonists, including tamoxifen and fulvestrant) and HER2-positive BC (treated with therapeutic antibodies, such as trastuzumab, and small molecules, such as lapatinib) (3–5).